{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:06:41Z","timestamp":1776722801587,"version":"3.51.2"},"reference-count":24,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Anaphylaxis is a rarely reported yet potentially fatal adverse effect of apixaban. This case involves a patient in her 60s who presented with left leg swelling and was diagnosed with bilateral deep vein thrombosis. Less than an hour after ingestion of therapeutically indicated apixaban, she experienced dyspnoea, hypoxia, hypotension and an urticarial rash. She was promptly treated with epinephrine, diphenhydramine and methylprednisolone and found to have an elevated tryptase level, a reliable marker for anaphylactic reactions. She clinically improved, transitioned to enoxaparin and was discharged the following day. This case encourages healthcare providers to consider anaphylaxis as a rare but potentially lethal side effect of apixaban.<\/jats:p>","DOI":"10.1136\/bcr-2026-272624","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:25:34Z","timestamp":1774977934000},"page":"e272624","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Apixaban-induced anaphylaxis"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9636-0688","authenticated-orcid":false,"given":"Jessica Hyunji","family":"Park","sequence":"first","affiliation":[{"name":"Division of Hospital Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett James","family":"Schuchardt","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che Mathew","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"2026033110252519000_19.3.e272624.1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05904-0"},{"key":"2026033110252519000_19.3.e272624.2","unstructured":"Bristol-Myers Squibb Company . Eliquis (apixaban) package insert. Available: https:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf [Accessed 14 Jan 2026]."},{"key":"2026033110252519000_19.3.e272624.3","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.jaip.2017.12.007","article-title":"Apixaban Causing Leukocytoclastic Vasculitis","volume":"6","author":"Nasir","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026033110252519000_19.3.e272624.4","article-title":"Apixaban as a Rare Cause of Leukocytoclastic Vasculitis","volume":"2020","author":"Spears","year":"2020","journal-title":"Case Rep Rheumatol"},{"key":"2026033110252519000_19.3.e272624.5","doi-asserted-by":"crossref","DOI":"10.5070\/D32610050473","article-title":"Apixaban-induced cutaneous hypersensitivity: a case series with evidence of cross-reactivity","volume":"26","author":"Isaq","year":"2020","journal-title":"Dermatol Online J"},{"key":"2026033110252519000_19.3.e272624.6","article-title":"Apixaban (Eliquis)-Induced Rash: A Case Report","volume":"15","author":"Nadella","year":"2023","journal-title":"Cureus"},{"key":"2026033110252519000_19.3.e272624.7","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/S0735-1097(23)03358-2","article-title":"Apixaban induced anaphylactic reaction","volume":"81","author":"Patel","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026033110252519000_19.3.e272624.8","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e3283036a90"},{"key":"2026033110252519000_19.3.e272624.9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2021.02.012","article-title":"Non-IgE-mediated anaphylaxis","volume":"147","author":"Cianferoni","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026033110252519000_19.3.e272624.10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejim.2022.03.003","article-title":"Adult anaphylaxis: A state-of-the-art review","volume":"100","author":"Rossi","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2026033110252519000_19.3.e272624.11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ajem.2018.05.009","article-title":"Biphasic anaphylaxis: A review of the literature and implications for emergency management","volume":"36","author":"Pourmand","year":"2018","journal-title":"Am J Emerg Med"},{"key":"2026033110252519000_19.3.e272624.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1303"},{"key":"2026033110252519000_19.3.e272624.13","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World allergy organization anaphylaxis guidance 2020","volume":"13","author":"Cardona","year":"2020","journal-title":"World Allergy Organ J"},{"key":"2026033110252519000_19.3.e272624.14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00614","article-title":"Epidemiology, Mechanisms, and Diagnosis of Drug-Induced Anaphylaxis","volume":"8","author":"Monta\u00f1ez","year":"2017","journal-title":"Front Immunol"},{"key":"2026033110252519000_19.3.e272624.15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026033110252519000_19.3.e272624.16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/JAA.S413057","article-title":"Suspected Rivaroxaban-Induced Anaphylaxis Secondary to Ingestion of Rivaroxaban and Nimesulide Without Cross-Reactivity to Dabigatran - A Case Report","volume":"16","author":"Gumbis","year":"2023","journal-title":"J Asthma Allergy"},{"key":"2026033110252519000_19.3.e272624.17","doi-asserted-by":"crossref","DOI":"10.11604\/pamj.2021.38.333.28401","article-title":"Anaphylaxis following rivaroxaban ingestion: report of an extremely rare case","volume":"38","author":"Khan","year":"2021","journal-title":"Pan Afr Med J"},{"key":"2026033110252519000_19.3.e272624.18","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0735-1097(21)03225-3","article-title":"Rivaroxaban induced anaphylaxis, a rare non-hemorrhagic adverse event","volume":"77","author":"Hamid","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026033110252519000_19.3.e272624.19","first-page":"213","article-title":"A rare side effect seen due to the use of apixaban: Palmoplantar psoriasiform drug eruption","volume":"16","author":"Veliyev","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"2026033110252519000_19.3.e272624.20","first-page":"181","article-title":"Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban","volume":"13","author":"Anis","year":"2021","journal-title":"Clin Pharmacol"},{"key":"2026033110252519000_19.3.e272624.21","doi-asserted-by":"crossref","first-page":"A2986","DOI":"10.1016\/j.chest.2024.06.1800","article-title":"A RARE CASE OF APIXABAN-INDUCED ANGIOEDEMA","volume":"166","author":"Modugula","year":"2024","journal-title":"Chest"},{"key":"2026033110252519000_19.3.e272624.22","doi-asserted-by":"crossref","DOI":"10.1177\/2473974X18805431","article-title":"Angioedema Involving the Larynx after Starting Apixaban","volume":"3","author":"Williamson","year":"2019","journal-title":"OTO Open"},{"key":"2026033110252519000_19.3.e272624.23","article-title":"Anaphylactic Shock Due to Technetium (99mTc)-Tetrofosmin During Myocardial Perfusion Scintigraphy: A Case Report","volume":"16","author":"Hashimoto","year":"2024","journal-title":"Cureus"},{"key":"2026033110252519000_19.3.e272624.24","doi-asserted-by":"crossref","DOI":"10.1007\/s40800-019-0097-4","article-title":"Anaphylactic Reaction to Tc-99m Macrosalb","volume":"6","author":"Schreuder","year":"2019","journal-title":"Drug Saf Case Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-272624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:25:37Z","timestamp":1774977937000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-272624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,31]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bcr-2026-272624"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-272624","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}